Skip to Main Content

Paper Details

AKT mutant allele-specific activation dictates pharmacologic sensitivities.
Nat Commun
7
2022
AKT, AKT isoforms, AKT mutant, AKT mutations, AKT1, AKT1 E17K, AKT1-3, ATP, AZD5363, E17K, E17K mutations, PI-3K, allele, altered cancer cell, cancer, capivasertib, in-frame duplications, oncogenic AKT mutants, patients, solid cancer, solid tumors, tumor, tumor cells
Author NameAffiliation
Debyani ChakravartyMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Wassim AbidaMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Barry S TaylorWeill Cornell Medical College
Barry S Taylor
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Barry S TaylorWeill Cornell Medical College
Barry S Taylor
  • 1 - 12

Datasets

Release 1.2